Chemistry:Ligelizumab
From HandWiki
Short description: Monoclonal antibody
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | IGHE |
| Clinical data | |
| Other names | QGE031 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6534H10000N1716O2038S44 |
| Molar mass | 146612.49 g·mol−1 |
Ligelizumab (INN; development code QGE031) is a humanized IgG1 monoclonal antibody designed for the treatment of severe asthma and chronic spontaneous urticaria.[1] It is an anti-IgE that binds to IGHE an acts as an immunomodulator.[2][3]
This drug was developed by Novartis Pharma AG. Research funded by Novartis Pharma[4] concluded that Ligelizumab was more effective in treating chronic spontaneous urticaria than omalizumab or placebo.[5]
References
- ↑ Novartis Pharma AG (29 October 2014). "Ligelizumab". Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/ligelizumab.pdf.
- ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107". WHO Drug Information 26 (2). 2012. https://www.who.int/medicines/publications/druginformation/innlists/Final_PL107.pdf.
- ↑ "Looking forward to new targeted treatments for chronic spontaneous urticaria". Clinical and Translational Allergy 7: 1. 2017-01-10. doi:10.1186/s13601-016-0139-2. PMID 28078079.
- ↑ Clinical trial number NCT02477332 for "A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)" at ClinicalTrials.gov
- ↑ "Ligelizumab for Chronic Spontaneous Urticaria". The New England Journal of Medicine 381 (14): 1321–1332. October 2019. doi:10.1056/NEJMoa1900408. PMID 31577874.
 |  |
